Radius Health (RDUS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Radius Health Announces Fourth Quarter and Full-Year 2019 Operating Results
February 27, 2020 7:30 AM ESTTYMLOS® U.S. net sales grew to $56 million in the fourth quarter of 2019,
 totaling $173M for full-year 2019, exceeding the Companys guidance of $168 to 172M
TYMLOS exited 2019 with majority share in new patients1, on track for market leadership in 2020
2020 TYMLOS U.S. net revenue expected to be between $220 and $235M and  full-year cash burn expected to be below $80M
Recruitment of three Phase 3 studies is advancing and expected to be completed in 2020, with anticipated data read-outs in... More
